Embody
  • Get Started
  • Our Top Products
  • GLP-1 Science
  • What To Expect
  • Market Leading Cost
  • FAQ
  • Contact Us

TCPA Compliance Policy

Embody


We at Embody provide our users the ability to receive certain types of information via email and/or text messaging, including healthcare-related messages on behalf of your healthcare provider. Above all, we are committed to protecting the privacy of our users. When you consent to receive email and text messages from Embody, you are agreeing to the terms outlined below. All names, email addresses, and/or telephone numbers of patients are protected in accordance with applicable privacy laws.

By consenting to receive messaging from Embody, you expressly consent to allow us to email and/or text you (via SMS and/or MMS) with or regarding marketing (including but not limited to calls or texts sent using an automatic telephone dialing system or an artificial or prerecorded voice), Personal Data (as defined in our Privacy Policy), appointments with your healthcare provider, or similar matters related to your healthcare provided by your healthcare provider, using the contact information you have provided. Additionally, you acknowledge that emails and text messages may not be a secure method of communication. They are sent through an unencrypted method of communication, meaning that information contained in an unencrypted message is at risk of being intercepted and read by, or disclosed to, unauthorized third parties, such as your mobile operator's text messaging system. Your phone carrier's normal rates may apply if you have consented to receive text messages. This consent is not a condition of purchasing or receiving services, and you may revoke this consent at any time by replying STOP to an email or text message or emailing us at: support@bloome.health.

BY OPTING INTO RECEIVING SMS AND EMAIL MESSAGES, YOU ACKNOWLEDGE YOU HAVE READ AND UNDERSTAND THE TERMS PRESENTED ABOVE, AND BY ACCEPTING THESE TERMS, YOU GIVE YOUR INFORMED CONSENT TO RECEIVE EMAIL AND/OR TEXT MESSAGES FROM EMBODY ON BEHALF OF ITSELF AND YOUR HEALTHCARE PROVIDER UNDER THESE TERMS.


How to Opt Out

You may opt out of receiving text messages or emails at any time by:

  1. Replying STOP to any text message you receive from us
  2. Clicking the unsubscribe link in any marketing email
  3. Emailing us at support@bloome.health with your opt-out request

Important Information

  • Message Frequency: Message frequency varies based on your healthcare needs and preferences
  • Carrier Charges: Standard message and data rates may apply
  • Security Notice: SMS and email are not secure forms of communication. Please do not send sensitive health information via text message unless specifically instructed by your healthcare provider
  • No Purchase Required: Consenting to receive messages is not required to purchase or receive services from Embody

Supported Carriers

Our text messaging service is compatible with all major U.S. wireless carriers including AT&T, Verizon, T-Mobile, Sprint, and others.


Contact Information

For questions about this policy or to manage your communication preferences:

Embody
1811 Silverside Road, Suite 260, Wilmington, DE 19180
Email: support@bloome.health
Website: thepeptidestacks.com


Last Updated: February 10, 2026

Embody
  • 1811 Silverside Road, Suite 260, Wilmington, DE 19180
  • Login

*The assessment made available on the Embody website does not create a doctor-patient relationship between the individual completing the assessment and Embody. Our affiliated network of independent, US-licensed providers, who adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the Embody assessment consequently determine if the individual is screened out of eligibility for GLP-1 medication, and a licensed clinician will meet with an individual after checkout to determine if they qualify for a prescription. Licensed clinicians retain the decision to prescribe compounded GLP-1s to patients.

All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results may vary and be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and medical history.

We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. Embody does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Pharmacy Providers
We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Embody patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

Medication is included in the cost of the Embody Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, and trade names (Wegovy®, Ozempic®) displayed on this website are protected and belong to their respective owners. Medical treatment is provided by independent licensed providers. No data, photos, claims or any other information is associated with results derived from clinical trials, studies or public information and is always representative of Embody patient experience.

Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content. Individuals appearing in advertisements may be actors or models.

Testimonials on the website are from Embody patients. For patient privacy, images representing those testimonials may use models.

By accepting our Terms of Use, you additionally understand and agree that Embody is not acting as a pharmacy, nor does Embody control or interfere with any such services. By accepting these Terms of Use, you understand and agree that you may be entering into a relationship with a pharmacy, pharmacist, and/or pharmacy group or other such relationship with any one or more such third-party entities. Prescriptions, if issued, are filled by licensed partner pharmacies.

Partner Pharmacies

© 2026 Embody. All rights reserved.

Terms & ConditionsPrivacy PolicyPrivacy PracticesRefund PolicyMedical ConsentFor California ResidentsBill of RightsSafety & Side EffectsTCPA Compliance Policy